Abstract
Efficacy and safety of briakinumab in moderate to severe psoriasis patients with prior failure to TNF antagonist: Subanalysis of a 52-week phase III trial and open-label extension
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
